Advertisement


Martine J. Piccart-Gebhart, MD, PhD, on Personalizing Treatments in HR-Positive/HER2-Negative Breast Cancer

ASCO 2026

Advertisement

Martine J. Piccart-Gebhart, MD, PhD, of Jules Bordet Institute, Université Libre de Bruxelles, reviews multiple abstracts discussing avenues of personalized treatment for patients with hormone receptor (HR)-positive, HER2-negative breast cancer, including genomic testing and systemic therapy.



Related Videos

Hepatobiliary Cancer

Daneng Li, MD, on Tegavivint in Advanced HCC

Daneng Li, MD, of City of Hope, discusses dose-finding results from a phase I/II trial of tegavivint, a downstream Wnt/β-catenin inhibitor, in patients with advanced hepatocellular carcinoma (HCC) (Abstract 4015). 

Hepatobiliary Cancer

Lorenza Rimassa, MD, and David James Pinato, MD, PhD, on Expanding the HCC Treatment Landscape: TACE Combinations, Immunotherapies, and Bispecific Antibodies

Lorenza Rimassa, MD, of IRCCS Humanitas Research Hospital, and David James Pinato, MD, PhD, of Imperial College London, discuss positive phase III findings in intermediate-stage hepatocellular carcinoma (HCC) with immunotherapy-based combinations with TACE, second-line data from IMbrave251, and novel targeted and bispecific antibody therapies. 

Gastroesophageal Cancer

Samuel J. Klempner, MD, FASCO, on Advanced HER2-Negative Gastroesophageal Cancer: Ivonescimab Plus FOLFOX

Samuel J. Klempner, MD, FASCO, of Mass General Brigham Cancer Institute, discusses a single-arm phase II study—which is currently open and enrolling (ClinicalTrials.gov identifier NCT07070466)—evaluating ivonescimab in combination with FOLFOX as front-line therapy in locally advanced, unresectable, or metastatic HER2-negative gastroesophageal adenocarcinoma (Abstract TPS4246).

Prostate Cancer

Atish Choudhury, MD, PhD, on Can Patients With an Exceptional Response to ARPIs Interrupt ADT?

Atish Choudhury, MD, PhD, of Dana-Farber Cancer Institute, talks about findings from the phase II A-DREAM/Alliance A032101 trial, which explored the possibility of androgen-deprivation (ADT) interruption in patients with metastatic hormone-sensitive prostate cancer who had an exceptional response to androgen receptor pathway inhibitors (ARPIs) (Abstract 5004). 

Lymphoma

Manali Kamdar, MD, on Rapid Oral Abstract Highlights: Three Emerging Trends in Lymphoma Care

Manali Kamdar, MD, of the University of Colorado, discusses a rapid oral abstract session that highlighted three trends in the field of lymphomas: improving outcomes in frontline diffuse large B-cell lymphoma, continued development of cellular therapies, and expanding molecular profiling. 

Advertisement

Advertisement




Advertisement